Precision BioSciences Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Update
- Advancing ARCUS® Platform by Developing In Vivo Gene Editing Programs for Genetic Diseases and Ex Vivo CAR T Therapies for Hematologic Malignancies - Presented Allogeneic CAR T Clinical Data at the…
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2021 Results on March 15, 2022
DURHAM, N.C. --(BUSINESS WIRE)--Mar. 8, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS ® -based ex vivo allogeneic CAR T and in vivo gene…
Precision BioSciences to Present at the 40th Annual J.P. Morgan Health Care Conference
DURHAM, N.C. --(BUSINESS WIRE)--Jan. 4, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing ex vivo allogeneic CAR T therapies and in vivo therapies…
Precision BioSciences Completes Spin-Out of Elo Life Systems
DURHAM, N.C. --(BUSINESS WIRE)--Dec. 21, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing ex vivo allogeneic CAR T therapies and in vivo therapies…
Precision BioSciences Reports Clinical Program Updates for Its Allogeneic CAR T Pipeline
- Precision BioSciences is Simultaneously Advancing Development of PBCAR0191, as Potential First-in-Class, and PBCAR19B as Potential Best-in-Class CD19 Targeting Allogeneic CAR T Therapies - High…
Precision BioSciences to Host Virtual Webcast and Conference Call to Review Interim Phase 1/2a PBCAR0191 CAR T Data and Provide CAR T Program Updates on Saturday, December 11, 2021
DURHAM, N.C. --(BUSINESS WIRE)--Dec. 6, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS® genome editing platform to develop allogeneic CAR T…
Precision BioSciences to Present Preclinical Gene Editing Data on its ARCUS-Based Chronic Hepatitis B Program at the HEP DART 2021 Conference
DURHAM, N.C. --(BUSINESS WIRE)--Dec. 3, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS® genome editing platform to develop allogeneic CAR T…
Precision BioSciences Reports Third Quarter 2021 Financial Results and Provides Business Update
- Appointed Michael Amoroso as President and Chief Executive Officer and to Board of Directors; Sam Wadsworth , Ph.D., and Shari Lisa Piré, J.D., Appointed to Board of Directors - Hosted In Vivo Gene…
Precision BioSciences to Highlight Capabilities of ARCUS Gene Editing for Allogeneic CAR T Cell Immunotherapies at The Society for Immunotherapy of Cancer 36th Annual Meeting
DURHAM, N.C. --(BUSINESS WIRE)--Nov. 9, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS® genome editing platform to develop allogeneic CAR T…
Precision BioSciences Appoints Sam Wadsworth, Ph.D. and Shari Lisa Piré, J.D. to Board of Directors
New Directors Add Decades of Cell and Gene Therapy Development and Strategic Business Growth Experience DURHAM, N.C. --(BUSINESS WIRE)--Nov. 8, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a…